News

Promising Outcomes from Plus Therapeutics' Clinical Trial for REYOBIQ

Promising Outcomes from Plus Therapeutics' Clinical Trial for REYOBIQ

Exciting Results from Plus Therapeutics on REYOBIQ Trial

Key findings show REYOBIQ achieved a remarkable clinical benefit rate exceeding 75% across various important outcome measures.

Analysis indicates RNA sequencing and a reduction in circulating tumor cells align with observed tumor cell death.

Additionally, the treatment displayed a favorable safety profile, with no significant dose-limiting toxicities noted.

In a major update from an important clinical trial, Plus Therapeutics, Inc. has unveiled optimistic data concerning its innovative treatment, REYOBIQ, aimed at tackling leptomeningeal metastases (LM). This information was shared during a notable forum at a conference focusing on central nervous system interactions, revealing that this therapy could become a viable option for patients grappling with this challenging condition.

Plus Therapeutics, a clinical-stage biopharmaceutical company known for pioneering targeted radiotherapeutics, reported on the positive outcomes from the ReSPECT-LM Phase 1 single-dose escalation trial. This trial involved 29 subjects and exhibited the feasibility of using REYOBIQ to treat LM while demonstrating safety and encouraging efficacy signals.

Significant Clinical Findings from REYOBIQ Treatment

In the study titled, “Phase 1 Dose Escalation of Rhenium (186Re) Obisbemeda (REYOBIQ) for the Treatment of Leptomeningeal Metastases: Results on Safety and Efficacy,” researchers documented crucial results gathered from patients receiving different doses of REYOBIQ, showcasing its potential.

Key Highlights from the Trial

Among the findings presented were impressive response rates; specifically, a radiographic response of 76% and an even higher clinical response rate of 87% up until day 112 of the trial. Additionally:

  • CSF tumor cell enumeration assays showed a maximum 100% reduction in tumor cells at day 28 from baseline.
  • Notably, five of the seven participants with a tumor cell enumeration response over 80% survived for at least one year.
  • The median overall survival across several cohorts was noted as 9 months, which is a significant improvement compared to historical data reporting average survival times of around four months.
  • Importantly, there were no serious dose-limiting toxicities in the initial cohorts, though one was observed at higher dose levels.
  • The most common side effects identified throughout the trial were primarily grade 1 or 2 in severity.

Dr. Andrew Brenner, a key investigator in this research, emphasized the encouraging nature of these results, underscoring that initial cohorts showed exceptional tolerance at elevated doses. He expressed that these insights are crucial for progressing into further trials and potentially towards approval.

Understanding Leptomeningeal Metastases

Leptomeningeal metastases, although rare, are a grave concern for advanced cancer patients. They involve the spread of cancer to the central nervous system’s protective membranes. This condition afflicts about 5% of individuals with metastatic cancers, particularly stemming from breast, lung, and melanoma origins. Survivability rates often range from just two to six months, emphasizing the pressing requirement for new treatment alternatives.

What is REYOBIQ?

REYOBIQ, or rhenium Re186 obisbemeda, represents a cutting-edge injectable radiotherapy designed to deliver concentrated targeted radiation directly to CNS tumors with enhanced safety, projecting an optimistic outlook for patient recovery compared to existing therapies. Its design utilizes rhenium-186, chosen for its effective properties in targeting and destroying cancer cells while enabling real-time imaging capabilities.

This promising product is currently being explored for use in recurrent glioblastoma and pediatric brain cancers in addition to its application in LM, supported by various grants from esteemed institutions like the National Cancer Institute and the Cancer Prevention & Research Institute of Texas.

About CNSide Diagnostic, LLC

CNSide Diagnostics, LLC, a subsidiary of Plus Therapeutics, plays a crucial role by developing advanced diagnostic tests to identify tumor cells metastasized to the central nervous system. Their innovative CNSide CSF assay allows for detailed analysis of tumor cells showcasing a commitment to improving the treatment landscape for patients dealing with leptomeningeal metastases.

About Plus Therapeutics

Based in Houston, Texas, Plus Therapeutics, Inc. focuses on developing targeted therapies aimed at serious CNS cancers, striving to boost clinical outcomes through novel approaches that integrate image-guided therapy with drug delivery systems. The company is dedicated to advancing its robust pipeline in the field, which includes tackling challenging conditions such as LM and recurrent glioblastoma.

By establishing strong partnerships, Plus Therapeutics ensures a reliable supply chain supporting the development and future commercialization of its promising products.

Frequently Asked Questions

What are the primary results from the REYOBIQ clinical trial?

The trial showed a clinical benefit rate of over 75%, with significant reduction in tumor cells and manageable safety profile.

How does REYOBIQ work?

REYOBIQ is a targeted radiotherapy that delivers high doses of radiation specifically to CNS tumors, minimizing off-target effects.

What is the significance of leptomeningeal metastases?

LM is a serious complication of advanced cancer, often leading to a very limited survival period due to few effective treatment options.

Who funded the ReSPECT-LM trial?

The trial is supported by a grant from the Cancer Prevention & Research Institute of Texas.

What is the future outlook for Plus Therapeutics?

The company is advancing into more trials aimed at further optimizing dosing and exploring approval for REYOBIQ.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

New York Reclaims Bagel Crown at 2026 BagelFest

Updated Category News Views 147

A Bagel Victory at Citi Field Holy schmear! New Yorker's are grinning wide like a bagel with a double helping of cream cheese—Ess-a-Bagel from Manhattan snagged the top honors at the heavily contested 2026 New York BagelFest. Back in its rightful hands, the Bagel Crown stays in the Empire State, and it's a victory for tradition and taste. Celebrating 50 years in the...

Continue Reading
SGRY Acquisition Under Scrutiny: Fairness Questioned

Updated Category News Views 124

Questions Hover Over SGRY Acquisition Here's a real jaw-dropper for you. Surgery Partners, Inc. (NASDAQ: SGRY) is getting clocks cleaned in a fairness probe over its acquisition terms. If you thought this ride was smooth, think again—Levi & Korsinsky, LLP has put the brakes on any such assumptions, launching an investigation that’s sure to raise some eyebrows. What's...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 71

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
Trades Workforce Shortage Costs Wallop U.S. Economy

Updated Category News Views 113

The Forgotten Backbone of America Don't sleep on this: America's got itself a trade worker crisis, and it's not just a numerical hiccup. We’re down nearly 1.9 million skilled trades workers, and that's a gut punch to the economy—a hefty $1.2 billion a day in GDP loss. These are the folks who keep the wheels greased, the lights on, and the goods flowing. Without them,...

Continue Reading
Stephanie L. Beiermann Shines in HR Consulting Honors

Updated Category News Views 54

Celebrating a Star in Payroll Optimization Ah, the name Stephanie L. Beiermann’s been making the rounds lately, catching eyes with her lauded expertise in payroll optimization and human resources. This recognition doesn’t come out of thin air—no, it’s anchored on a solid foundation of over 25 years of cutting through the fluff to sharpen operational edges. We’re...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 250

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Québecor Makes Its Move: Eye on TELUS Amid Telecom Shakeup

Updated Category News Views 58

The Offer That Shocked the Telecom Markets Just when you think you’ve figured out the lay of the land, someone throws a curveball. Québecor’s decision to take a run at TELUS is shaking up Canada’s telecom scene big time. This isn’t just another M&A whisper; it’s a roaring freight train of a proposal valued at a whopping $31 billion. And TELUS, not just sitting...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 126

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 152

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
Zettia R. Barnes: Charting a Path in Home Healthcare

Updated Category News Views 62

The Lifeline of Home Healthcare in DeSoto You know, it ain't every day that someone like Zettia R. Barnes steps up in the realm of home healthcare and makes a mark that genuinely sticks. From rubbing shoulders with patients to steering a whole dang organization like Angels of Hands Home Health Agency Corp., she's got her hands full—and frankly, it’s folks like her who...

Continue Reading

Top 5 Most Recently Viewed Articles

Blain’s Farm & Fleet Shines in Newsweek’s Best Online Shops

Updated Category News Views 97

Blain’s Farm & Fleet Achieves Recognition for Online Excellence Blain's Farm & Fleet, a well-respected name in retail, has been honored as one of Newsweek’s Best Online Shops for 2025. This recognition marks the fourth consecutive year the company has earned this prestigious title, reflecting its unwavering commitment to quality and service across its online platform....

Continue Reading
Statkraft AS Secures NOK 3 Billion Through Commercial Paper

Updated Category News Views 127

Statkraft AS Secures Significant Funding Statkraft AS has successfully issued a commercial paper totaling NOK 3.0 billion, showcasing the company's strategic approach to financing. This financial instrument offers a coupon rate of 3M NIBOR plus 0.205%, reflecting favorable conditions in financial markets. Details of the Commercial Paper The commercial paper is designed...

Continue Reading
Soleno Therapeutics Launches $100 Million Stock Buyback Program

Updated Category News Views 143

Soleno Therapeutics Initiates Major Buyback Program Soleno Therapeutics Inc. (NASDAQ: SLNO) has announced a significant development in its corporate strategy by launching a $100 million share repurchase program. This move comes as the company seeks to enhance shareholder value amidst an environment where its stock has been deemed undervalued by market analysts. Details of...

Continue Reading
Brentwood Associates Launches $410 Million Fund for Watermill

Updated Category News Views 383

Overview of the New Continuation Fund Brentwood Associates, a leading private equity firm known for its strategic and growth-oriented investments, has officially closed an impressive $410 million continuation fund aimed at fueling the expansion of Watermill Express, LLC. This fund's purpose is to enhance the operational capabilities of Watermill Express, a prominent...

Continue Reading
Great Lakes Dredge & Dock Corporation Upgraded to B- Rating

Updated Category News Views 105

Great Lakes Dredge & Dock Corporation Receives S&P Upgrade Great Lakes Dredge & Dock Corporation ("Great Lakes" or the “Company”) (NASDAQ: GLDD), the leading provider of dredging services in the United States, has announced a notable upgrade to its issuer credit rating by S&P Global Ratings. The rating has been elevated from “CCC+” to “B-,” signaling a...

Continue Reading